A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).
Clinical trial NCT04760288 · WITHDRAWN
Trial details
- NCT number
- NCT04760288
- Sponsor
- Hoffmann-La Roche
- Status
- WITHDRAWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-30
- Primary completion
- 2027-10-06
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.